The British Regional Heart Study (BRHS) reported in 1986 that much of the inverse relation of high-density lipoprotein cholesterol (HDLC) (MRFIT). In CPPT and MRFIT (both randomized trials in middle-aged high-risk men), only the control groups were analyzed. A 1-mg/dl (0.026 mM) increment in HDLC was associated with a significant coronary heart disease risk decrement of 2% in men (FHS, CPPT, and MRFIT) and 3% in women (FHS). In LRCF, where only fatal outcomes were documented, a 1-mg/dl increment in HDLC was associated with significant 3.7% (men) and 4.7% (women) decrements in cardiovascular disease mortality rates. The 95% confidence intervals for these decrements in coronary heart and cardiovascular disease risk in the four studies overlapped considerably, and all contained the range 1.9-2.9%. HDLC levels were essentially unrelated to non-cardiovascular disease mortality. When differences in analytic methodology were eliminated, a consistent inverse relation of HDLC levels and coronary heart disease event rates was apparent in BRHS as well as in the four American studies. (Circulation 1989;79:8-15 
mortality rates. The 95% confidence intervals for these decrements in coronary heart and cardiovascular disease risk in the four studies overlapped considerably, and all contained the range 1.9-2.9%. HDLC levels were essentially unrelated to non-cardiovascular disease mortality. When differences in analytic methodology were eliminated, a consistent inverse relation of HDLC levels and coronary heart disease event rates was apparent in BRHS as well as in the four American studies. (Circulation 1989; 79:8-15) T rends relating high plasma levels of highdensity lipoprotein cholesterol (HDLC) and decreased incidence of cardiovascular disease endpoints have been observed in prospective epidemiological studies conducted in several countries.1-12 The report from one of these studies, the British Regional Heart Study (BRHS), in which 7,415 men, aged 40-59 years, were followed for an average of 4.2 years, suggested that HDLC was not a significant risk factor for ischemic coronary heart disease (CHD) after statistical adjustment for other risk factors.9 Because comparisons of these studies are confounded by differences in their statistical methods and in the populations and cardiovascular endpoints studied, we have undertaken a systematic reexamination of two major North American population-based studies, the Participants were examined annually for determination of risk factors and disease occurrence for an average of 6.7 years. Vital status was ascertained in 99.7% of the cohort. The definitions and mechanisms for endpoint diagnosis were similar to those in the CPPT.
Laboratory Methods
Lipid and lipoprotein determinations were performed on fresh plasma samples collected after at least 12 hours of fasting.20 Cholesterol levels were determined by the Abell-Kendall method21 in FHS and by the Technicon AutoAnalyzer (standardized to the Abell-Kendall method)20 in LRCF, CPPT, and MRFIT. Manganese-heparin precipitation was used in measuring HDLC in all four studies.20 Plasma LDLC levels were determined by ultracentrifugation20 and plasma very low-density lipoprotein cholesterol (VLDLC) levels were estimated as one fifth the plasma triglyceride level. 22 Statistical Methods CHD incidence and CHD, CVD, and all-cause mortality rates (events per 1,000 person-years) were calculated for subgroups of each cohort defined by HDLC levels as "high" (.50 mg/dl or 1.30 mM), "medium" (40-50 mg/dl), or "low" (<40 mg/dl or 1.04 mM). In FHS and LRCF, men and women were analyzed as separate cohorts.
Cox's proportional hazards model23 was used to quantify the relation of HDLC levels to event rates and to adjust for other baseline risk factor levels. The regression coefficient (a) for HDLC was converted to a percent increment in risk corresponding to a 1 mg/dl (0.026 mM) increment in HDLC as follows:
a' = 100 * (e a_ 1) when the value of a is much less than 1, a' = 100* a.
The logistic regression coefficients relating HDL and non-HDL (NHDL) cholesterol levels to CHD incidence in BRHS9 were used to calculate the logistic coefficients of the algebraically equivalent alternative model containing HDL and total (TOT) cholesterol. Because NHDL=TOT-HDL by definition, a * HDL +b NHDL = (a -b) HDL +b TOT Thus, the total cholesterol-adjusted coefficient for HDL cholesterol can be calculated by subtracting the published coefficient for NHDL cholesterol (b) from the published coefficient for HDL cholesterol (a). Each logistic coefficient was then converted to a percent increment in risk for each 1 mg/dl (0.026 mM) increment in HDLC as described above.
Results
The mean values of HDLC and several other CHD risk factors in each study are provided in Crude incidence rates of CHD ( Figure 1A) were generally highest in participants with low HDLC (<40 mg/dl [1.04 mM]) and lowest in those with "high" HDLC (>50 mg/dl [1.30 mM] ). This inverse trend was most striking in FHS women, where incidence rates were 2.6 times higher in the former than latter HDLC stratum. Note that event rates within a given HDLC category should not be compared across studies without taking into account their differing CHD risk factor profiles (Table 2) as well as the absence of data on nonfatal myocardial infarction in LRCF.
Although CHD, CVD, and all-cause mortality rates ( Figure 1B ) also tended to be lowest among subjects with the highest HDLC levels, the numbers of fatal cardiovascular events were relatively small, and their relation to HDLC levels appeared more irregular. However, in both FHS and LRCF, CVD mortality rates were at least four times higher in low HDLC than in high HDLC women. When CVD mortality rates in FHS and CRCF women were compared with those of their male counterparts, their survival advantage was confined to the middle and high HDLC categories. No trend relating HDLC levels to non-CVD mortality rates was evident in men or women in FHS (not shown), LRCF, CPPT, and MRFIT ( Figure 1B) .
The relation of HDLC to each endpoint was quantified and adjusted for age, cigarette smoking, systolic blood pressure, body mass index, and LDLC levels by proportional hazards regression (Table 3) . Consistent with the univariate results ( Figure 1A ), significant inverse associations of HDLC and CHD incidence were observed in both men (FHS, CPPT, and MRFIT) and women (FHS). A hypothetical 1-ml/dl (0.026 mM) increment in HDLC was associated with a CHD risk decrement of 1.9-2.3% in men and 3.2% in women.
The regression models for mortality (Table 3) were also consistent with the corresponding univariate analyses ( Figure 1B ). In men, the regression coefficients relating HDLC levels to CHD and total CVD mortality in FHS, CPPT, and MRFIT were generally smaller than those for CHD incidence; none was statistically significant. However, in LRCF men, these two coefficients were highly significant (p <0.001) and were more than twice as large as those in the other three male cohorts. In both female cohorts, as in LRCF men, a 1-mg/dl (0.026 mM) increment in HDL was associated with a 3.7-4.7% decrement in CHD and total CVD mortality rates. The number of FHS and LRCF women dying of CHD was small (17 in both cohorts combined), and only the coefficients for total CVD mortality attained statistical significance. The coefficients relating HDLC to all-cause mortality were generally weak, reflecting the dilution of cardiovascular with unrelated causes of death; only those for LRCF men and women remained statistically significant.
The 95% confidence intervals for the regression coefficients relating HDLC levels to CHD incidence and CVD mortality in the four male and two female cohorts are compared in Figure 2 . Although these coefficients vary among studies, the corresponding In each of the five studies, the inverse relation of HDLC and CHD incidence was weaker for the model containing NHDLC than for any of the other models. However, except in FHS (p=0.06) and BRHS (p=0.21), the coefficient remained statistically significant. In FHS and MRFIT, adjustment for TOTC, LDLC, or both LDLC and VLDLC did not change the regression coefficient for HDLC from its unadjusted value. In LRCF, these covariance adjustments actually increased the magnitude of this coefficient. This coefficient decreased substantially after covariance adjustment only in the CPPT. Although LDLC and VLDLC levels were not obtained in BRHS and the unadjusted regression coefficient for HDLC was not reported, the values of the coefficients for HDLC in BRHS for models containing NHDLC or TOTC as covariates Table 4 provides no evidence to support a systematic difference between British and American men in the nature of the relation between HDLC and CHD.
The question remains of why NHDLC (which is, after all, simply the sum of LDLC and VLDLC) acts as a confounder of the HDLC-CHD relation, whereas its individual components, included as separate terms, do not. To act as a confounder, a variable must be associated with both the presumptive risk factor (HDLC) and the outcome (CHD incidence). In these data, LDLC meets only the latter criterion, whereas VLDLC meets only the former; thus, even when both terms are included separately as covariates, there is no confounding, and the HDLC coefficient is essentially unchanged. However, the composite variable NHDLC is associated both with CHD and (inversely) with HDLC, and its inclusion in the model weakens the inverse association of HDLC and CHD. Although this model is not "wrong" in an absolute sense, it gives a result that differs from models in which each lipoprotein species is represented by a separate term. If the latter type of model were used as the standard but (as in the BRHS, where blood specimens were not drawn in the fasting state) separate LDLC and VLDLC levels are unavailable, then the model containing HDLC and TOTC or HDLC alone will usually provide a "better" estimate of the relation between HDLC and CHD incidence than does the model containing HDLC and NHDLC.
We also considered the possible implications of another methodological difference-the use of the logistic model in BRHS and of the proportional hazards model in the current analysis. In general, these two models differ only when a substantial proportion of a cohort has had the event of interest, has died, or has been lost to follow-up.24 This was not true in any of the cohorts discussed here. Logistic models that we computed for LRCF and CPPT gave essentially the same results as the proportional hazards models.
Although the data relating HDLC and CVD mortality are relatively sparse and are not statistically compelling, they are generally consistent with the data for CHD incidence (Figure 2) . A 1-mg/dl increment in HDLC is associated with a 2-3% decrement in risk. Our analysis yielded no trends relating HDLC to increased non-CVD mortality rates as have been reported elsewhere. 4, 25, 26 In the Minneapolis study,4 in which 260 men were followed for 25 years with a 52% cumulative mortality rate, the trend in non-CVD mortality may be attributed (at least in part) to the opposing trend in CVD mortality; that is, men with low HDLC tend to die most often from CVD, and those with high HDLC tend to die most often from other causes. Life-table analyses that include the duration of survival, as well as the cause of death, are needed to determine whether there was any real benefit (or detriment) associated with a high HDLC level in this study. However, in the USSR study,25,26 the trend relating high HDLC levels to high non-CVD mortality was not offset by a trend toward fewer CVD deaths. Although such a result may be explained by patterns of alcohol consumption, it persisted after adjustment for self-reported habitual alcohol intake and other potential confounding variables.
In conclusion, the epidemiological data generally support an independent inverse association of HDLC levels and CHD event rates, in which CHD risk decreases by 2-3% for a 1-mg/dl (0.026 mM) increment in HDLC levels. Several hypothesized underlying mechanisms for this association have been advanced, most notably "reverse transport" of cholesterol by the HDL particle, but as yet, none has been clearly established. 27 Although clinical trials of cholesterol lowering in hypercholesterolemic men indicate that increases in HDLC may enhance the benefit of decreasing LDLC,12,28-30 the value of therapy aimed specifically at increasing HDLC levels remains unproven. However, the adoption of certain hygienic measures, such as exercise, weight loss, and smoking cessation, which are beneficial in their own right and may also raise HDLC levels,31,32 appear prudent.
